# Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Source: https://onco.cc/trials/nct04930432/  
OnCo record `nct04930432` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MCLA-129 in non-small-cell lung cancer and small-cell lung cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.

## Summary

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors is a phase 1/2 interventional study registered as NCT04930432 by Betta Pharmaceuticals Co., Ltd., with 400 participants planned, started 2021-09-24 and due to reach its primary completion in 2028-04-30. Interventions recorded: MCLA-129. Conditions listed: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04930432
- Phase: 1/2
- Setting: A Phase I/II Study of MCLA-129, a Human Anti-EGFR and Anti-c-Met Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors, Evaluating Safety, Pharmacokinetic Characteristics and Antitumor Activity
- Sponsor: Betta Pharmaceuticals Co., Ltd.
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT04930432: https://clinicaltrials.gov/study/NCT04930432

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [MCLA-129](https://onco.cc/drugs/mcla-129/)
- companies: [Betta Pharmaceuticals](https://onco.cc/companies/betta/)

---
JSON: https://onco.cc/api/v1/entities/nct04930432.json